Boston

Politics

Senators want to know if HHS money went to Chinese genomics firms

By Damian Garde

Biotech

Fast-growing Vericel finds success on two fronts: knee surgery and burn care

By Jonathan Saltzman — Boston Globe

Biotech

Merck to acquire Boston-area immunotherapy startup for up to $770 million

By Kate Sheridan

Health

Redefining normal: Study shows mutations even in healthy tissues throughout the body

By Brittany Flaherty

Biotech

Third Rock raises $770 million in new funding round

By Jonathan Saltzman — Boston Globe

Exclusive

One of the world’s best drug hunters went after Alzheimer’s. Here’s how he lost

By Matthew Herper

Business

Haven wants to help ‘the American public get better health and reduce the costs,’ JPMorgan CEO says

By Kate Sheridan

Biotech

Europe approves first gene therapy to treat rare blood disease

By Damian Garde

Biotech

Thrive, with $100 million, strides into the crowded race to develop a blood test to detect cancer

By Kate Sheridan and Matthew Herper

Health

The surgeon had a dilemma only a Nazi medical text could resolve. Was it ethical to use it?

By Sharon Begley

Biotech

A wave of NIH-backed microbiome research examines the gut’s link to diabetes, inflammatory bowel disease, and more

By Kate Sheridan

Pharma

At $2.1 million, newly approved Novartis gene therapy will be world’s most expensive drug

By Adam Feuerstein

Health

Former NFL players die at a faster rate than other professional athletes, study finds

By Shraddha Chakradhar

Pharmalot

Vertex and U.K. agency make competing proposals as logjam over cystic fibrosis meds continues

By Ed Silverman

In the Lab

At MIT, a bitter dispute over research puts a scientist’s prestige on the line

By Damian Garde and Megan Thielking

Biotech

Microbiome therapies could be the next frontier in medicine. But how exactly do you make them?

By Kate Sheridan

In the Lab

MIT professor is accused of claiming others’ scientific discoveries as his own

By Damian Garde

Health Tech

Singapore digital health startup raises $35 million, plans headquarters move to Boston

By Larry Edelman — Boston Globe

Biotech

Startup Spotlight: Flagship’s latest single-cell sequencing startup gets a name: Cellarity

By Kate Sheridan

Business

Departure of top Haven executive creates void at a crucial stage

By Casey Ross and Kate Sheridan

Health

Dana-Farber prevails in immunotherapy dispute over patents behind blockbuster drug

By Elizabeth Cooney

Biotech

As more dogs are tested for potential genetic diseases, experts say use caution

By Jonathan Saltzman — Boston Globe

Health

Brain training shows promise as a treatment for veterans’ cognitive problems after TBI

By Sharon Begley

Biotech

Vertex to pay startup Kymera $70 million in R&D deal

By Jonathan Saltzman — Boston Globe

In the Lab

Labs rack up big energy bills and produce a ton of trash. Many are trying to become more eco-friendly

By Megan Thielking

Is sexual desire a medical issue? An experimental drug for women revives an intense debate

What if AI in health care is the next asbestos?

Bluebird’s gene therapy for a rare blood disease will cost $1.8 million. Cue the pricing debate

Startup Spotlight: Akrevia Therapeutics eyes safer immunotherapies

Senators want to know if HHS money went to Chinese genomics firms

Fast-growing Vericel finds success on two fronts: knee surgery and burn care

Merck to acquire Boston-area immunotherapy startup for up to $770 million

Redefining normal: Study shows mutations even in healthy tissues throughout the body

Third Rock raises $770 million in new funding round

One of the world’s best drug hunters went after Alzheimer’s. Here’s how he lost

Haven wants to help ‘the American public get better health and reduce the costs,’ JPMorgan CEO says

Europe approves first gene therapy to treat rare blood disease

Thrive, with $100 million, strides into the crowded race to develop a blood test to detect cancer

The surgeon had a dilemma only a Nazi medical text could resolve. Was it ethical to use it?

A wave of NIH-backed microbiome research examines the gut’s link to diabetes, inflammatory bowel disease, and more

At $2.1 million, newly approved Novartis gene therapy will be world’s most expensive drug

Former NFL players die at a faster rate than other professional athletes, study finds

Vertex and U.K. agency make competing proposals as logjam over cystic fibrosis meds continues

At MIT, a bitter dispute over research puts a scientist’s prestige on the line

Microbiome therapies could be the next frontier in medicine. But how exactly do you make them?

MIT professor is accused of claiming others’ scientific discoveries as his own

Singapore digital health startup raises $35 million, plans headquarters move to Boston

Startup Spotlight: Flagship’s latest single-cell sequencing startup gets a name: Cellarity

Departure of top Haven executive creates void at a crucial stage

Dana-Farber prevails in immunotherapy dispute over patents behind blockbuster drug

As more dogs are tested for potential genetic diseases, experts say use caution

Brain training shows promise as a treatment for veterans’ cognitive problems after TBI

Vertex to pay startup Kymera $70 million in R&D deal

Labs rack up big energy bills and produce a ton of trash. Many are trying to become more eco-friendly

Boston

Sign up for our Daily Recap newsletter